Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
Establishment of Pharmacovigilance ProgrammeNipun Gupta
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
The International Council on Harmonisation (ICH) defines an institutional review board (IRB) as a group formally designated to protect the rights, safety and well-being of humans involved in a clinical trial by reviewing all aspects of the trial and approving its startup. IRBs can also be called independent ethics committees (IECs).
An IRB/IEC reviews the appropriateness of the clinical trial protocol as well as the risks and benefits to study participants. It ensures that clinical trial participants are exposed to minimal risk in relation to any benefits that might result from the research.
IRB/IEC members should be collectively qualified to review the scientific, medical and ethical aspects of the trial.
Per the FDA, an IRB/IEC should have:
At least five members.
Members with varying backgrounds.
At least one member who represents a non-scientific area (a lay member).
At least one member who is not affiliated with the institution or the trial site (an independent member).
Competent members who are able to review and evaluate the science, medical aspects and ethics of the proposed trial.
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
For better understanding of students. This will give you a detailed explanation of IND APPLICATION. Contact me through comment section if you need any assistance in understating this topic.
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
An Individual Case Safety Report (ICSR) is a document that contains information about a single adverse event or suspected adverse reaction to a medicinal product. It is a critical component of pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
ICSRs are typically generated by healthcare professionals, patients, or clinical trial investigators, and they include a detailed description of the adverse event, patient demographics, medical history, and details about the medicinal product(s) involved. The report also contains an assessment of the causal relationship between the adverse event and the medicinal product(s), as well as any medical interventions or outcomes that occurred.
ICSRs are essential for identifying potential safety issues with medicinal products and for assessing the risk-benefit profile of a product. They also help to ensure that regulatory authorities, such as the FDA or EMA, are notified of any safety concerns associated with a medicinal product.
ICSRs must comply with international reporting requirements, which specify the information that must be included in the report, as well as the timeframe for submission. The information in an ICSR must be accurate and complete to enable effective analysis and evaluation of the safety data.
ICSRs are a crucial aspect of pharmacovigilance and the regulatory process, as they provide valuable information for the ongoing evaluation of the safety of medicinal products. The prompt reporting of ICSRs is essential for ensuring the timely detection and assessment of any safety concerns associated with the use of medicinal products.
A presentation on Pharmacovigilance System in United States.
We at PharmXL International Pvt. Ltd., offer wide range of services for pharma industry like Pharmacovigilance services, Clinical Trials services, Regulatory Affairs services, Medical writing services etc to comply with required regulatory obligations across major regions.
For details visit: www.PharmXL.com
Email us: contact@pharmxl.com
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Establishment of Pharmacovigilance ProgrammeNipun Gupta
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
Definitions, Severity assessment, Seriousness assessment
Naranjo algorithm, Preventability assessment
By
Ms. B. Mary Vishali
Department of Pharmacology
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
The International Council on Harmonisation (ICH) defines an institutional review board (IRB) as a group formally designated to protect the rights, safety and well-being of humans involved in a clinical trial by reviewing all aspects of the trial and approving its startup. IRBs can also be called independent ethics committees (IECs).
An IRB/IEC reviews the appropriateness of the clinical trial protocol as well as the risks and benefits to study participants. It ensures that clinical trial participants are exposed to minimal risk in relation to any benefits that might result from the research.
IRB/IEC members should be collectively qualified to review the scientific, medical and ethical aspects of the trial.
Per the FDA, an IRB/IEC should have:
At least five members.
Members with varying backgrounds.
At least one member who represents a non-scientific area (a lay member).
At least one member who is not affiliated with the institution or the trial site (an independent member).
Competent members who are able to review and evaluate the science, medical aspects and ethics of the proposed trial.
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
For better understanding of students. This will give you a detailed explanation of IND APPLICATION. Contact me through comment section if you need any assistance in understating this topic.
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
An Individual Case Safety Report (ICSR) is a document that contains information about a single adverse event or suspected adverse reaction to a medicinal product. It is a critical component of pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
ICSRs are typically generated by healthcare professionals, patients, or clinical trial investigators, and they include a detailed description of the adverse event, patient demographics, medical history, and details about the medicinal product(s) involved. The report also contains an assessment of the causal relationship between the adverse event and the medicinal product(s), as well as any medical interventions or outcomes that occurred.
ICSRs are essential for identifying potential safety issues with medicinal products and for assessing the risk-benefit profile of a product. They also help to ensure that regulatory authorities, such as the FDA or EMA, are notified of any safety concerns associated with a medicinal product.
ICSRs must comply with international reporting requirements, which specify the information that must be included in the report, as well as the timeframe for submission. The information in an ICSR must be accurate and complete to enable effective analysis and evaluation of the safety data.
ICSRs are a crucial aspect of pharmacovigilance and the regulatory process, as they provide valuable information for the ongoing evaluation of the safety of medicinal products. The prompt reporting of ICSRs is essential for ensuring the timely detection and assessment of any safety concerns associated with the use of medicinal products.
A presentation on Pharmacovigilance System in United States.
We at PharmXL International Pvt. Ltd., offer wide range of services for pharma industry like Pharmacovigilance services, Clinical Trials services, Regulatory Affairs services, Medical writing services etc to comply with required regulatory obligations across major regions.
For details visit: www.PharmXL.com
Email us: contact@pharmxl.com
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Investigation of Medicinal Product Dossier (IMPD) and Investigator Brochure (...Tanvi Mhashakhetri
Contents:
European Medicines Agency (EMA)
IMPD Introduction
Contents of IMPD
Objectives
Scope
Introduction of IB
General Consideration
Content of IB
European Medicines Agency (EMA)
It is a decentralized agency of the European union.
The Management Board is the European Medicines Agency’s integral governance Body.
The Agency is responsible for the scientific evaluation, supervision and safety monitoring of the medicines developed by pharmaceutical companies use in EU.
EMA protects public and animal health in 27 EU member states, as well as the countries of the European economic area , by ensuring that all medicines available on the EU market are safe, effective and of high quality.
History
European medical agency was found in 1995, has worked across the EU and globally to protect public and animal healty by assessing medicines to rigorous scientific standards and providing with independent, science-based informations on medicines.
EMA has 20 year track record of ensuring efficacy and safety of human and veterinary medicines across Europe, and promoting research and innovation in the developments of medicines.
In first two decades, the agency recommended the authorization of the total of 975 humans and 188 veterinary medicines.
Clinical research : Drug regulatory affairs and Pharmacovigilance.ProfDnyaneshwariJosh
Schedule Y, FDA, Appendices, Post marketing surveillance,Clinical trial,WHO,ICH-GCP, FDA-CFR, Safety,Adverse Drug reaction, Adverse Event(AE), Serious Adverse Event(SAE),Reporting, IND , 3500A form
Pharmacovigilance (PV) plays a crucial role in ensuring the safety of drugs and monitoring their adverse effects. During an interview for a pharmacovigilance position or a related role, you may come across questions about the uses and importance of pharmacovigilance. Here are some potential interview questions related to the uses of pharmacovigilance
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...Pristyn Research Solutions
Quick Job interview short guide For Pharma and all Life science jobseekers.All Medical | Biotech |Micro |B.Sc., M.Sc.
These are the commonly asked questions with their answers asked in job interviews. The file was updated in 2022.
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4, Opposite To Expert Global, Garware Stadium Road, Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 9028839789
Sample Questions are:
What is Pharmacovigilance (PV)?
What are the objectives of PV?
What is MedDRA?
WHAT ARE THE Role of Drug Safety
Associate?
What should narratives consist of?
What are Data assessments in PV?
Which products are covered by PV?
Methods of signal detection?
Why PV is required after clinical
trial?
What is an Adverse Drug Event (ADE)?
What
is the minimum criterion required
for a valid case according to WHO?
When
do you consider an event to be
serious?
What do you mean by causality?
Types of
Unsolicited reports
Sources of Solicited Reports
Name the core regulatory bodies
What is Volume 9A
What do you know
about E2a, E2b and E2c guidelines?
When do you consider a case to be medically confirmed?
What is CemFlow?
What is the yellow card in PV?
What are Comorbid conditions?
What is a medication error?
What is a signal?
Rechallenge
Dechallenge
What are WHO ART, WHO DD and MedDRA and the difference between them?
What is SUSAR?
Adverse Drug Reaction (ADR)
Effectiveness/risk
harm
Essential medicines
Frequency of ADRs
Individual Case Safety Report
ADR Reporting process in PV
VigiFlow
VigiMed
ABBOTTS
COGNIZANT
I 3 GLOBAL DRUG
SAFETY
LAURUS LABS
PARAXEL
SRISTEK
ACCENTURE
CREST.
I GATE PATNI
COMPUTERS
MAHINDRA
SATYAMBSG
PIRAMAL
SUN
PHARMA
ALEMBIC
DIAGNOSEAR
CH
ICON
MAKROCARE
PPD
SYMOGEN
APC PHARMA.
DR REDDY’S
iMEDGlobal,
MANKIND
QUANTUM
SOLUTIONS
SYNOGEN
APCER
ECRON
ACUNOVA
IMS HEALTH
MEDHIMALAYAS
QUINTILES
TAKE
SOLUTIONS
APCER
EMCURE
INC RESEARCH
MEDPACE.
SCIFORMIX
RATIOPHARM
TCS
ASTRAZENECA
FDC
Infocorp
Soft
Solutions
MICRO LABS
RX MD
THOMSON
REUTERS
AUROBINDO
FORTIS
HEALTH CARE
INVENTIVE
MSD (MERCK)
SANTHA
BIOTECH
USV
LIMITED
BESTOCHEM
G7 INFOTECH
IPCA
LABORATORIES
NEKTAR
THERAPEUTICS
SCIFORMIX.
VIMTA LABS
BIOCAD
GENPACT
IPLEX
NORWICH
CLINICAL SERVICES
SHANTHA
BIOTECHNICS
WIPRO
BIOCON
GRANULES
JUBILIANT
BIOSYS NOVARTIS
SIRO
CLINPHARM
WNS
BIOLOGICAL E.
LTD
GVK
KINAPSE
NOVO NORDISK
SP softtech
WOCKHARD
T
BLUEFISH
HCL
LAMBDA
OMNICARECLINICA
L RESEARCH
SRI KRISHNA
PHARMA
4C
Pharma
Solutions
ICH GCP guidelines for mpharmacy 2nd sem 204T subject.
topic include the brief description regarding ICH GCP
THE GOOD CLINICAL PRACTICES AND
THE INTERNATIONAL CONFERENCE OF HORMONIZATION.
THAT INCLUDE the regulation of all pharmaceutical industries.
Similar to ICH Guidelines for Pharmacovigilance (20)
Definition of social pharmacy, social pharmacy as a discipline, scope of social pharmacy and role of pharmacist in public health, National Health Mission, National rural health mission, National urban health mission
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
3. Organization and objectives of ICH
INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) of Technical
Requirements for Pharmaceuticals for Human Use
◉ Established in April 1990
◉ Initiative for regulators and pharmaceutical industries
◉ Reformed as a non-profit legal entity under Swiss Law on 23 October
2015
◉ Formed to assure safety, quality and efficacy of medicines, the members
of ICH who include members from drug regulatory authorities and
research based industries of European Union, US and Japan will discuss
on the technical procedures and documents required.
3
4. Need for harmonization
◉ The difference in the technical requirements and the
procedures followed by different countries made the global
marketing of drugs as time consuming and expensive
◉ To reduce the cost and time required for the global
marketing of drugs
◉ Harmonization of technical requirements has to be promoted
◉ Special guidelines to be framed to ensure the quality, safety
and the efficacy of the drugs
5. Purpose or Objectives of ICH
◉ Harmonized interpretation and application of technical
guidelines and requirements for marketing authorization to:
Reduce duplication of testing of the drugs under
investigation
Increase economical use of resources
Eliminate unnecessary delay in availability of new
medicines
◉ Safeguarding quality, safety and efficacy
◉ Accomplished through Technical Guidelines that are
implemented by the regulatory authorities.
6. Categories agreed for Harmonization
◉ New types of medicinal products
◉ Lack of harmonization of current technical
requirements
◉ Transitions to technically improved testing
procedures
◉ Review of existing ICH guidelines resulting in
major changes &
◉ Maintenance of existing ICH guidelines
requirement minor changes
7. ICH Members
ICH covers 3 regions:
◉ European Union
◉ United States of America
◉ Japan
“Six Parties”
1. The European commission, (representing 28 members states of EU)
2. The European federation of pharmaceutical industries and associations (IFPMA)
3. The Ministry of Health, Labour and Welfare of Japan
4. The Japanese Pharmaceutical Manufactures Association (JPMA)
5. The US Food and drug Administration (FDA)
6. The Pharmaceutical Research and Manufacture of America (PhRMA)
8. ICH Members
18 Members:
Founding Regulatory Members
◉ European Union
◉ FDA, United States of America
◉ MHLW/PMDA, Japan
Founding Industry Members
◉ EFPIA
◉ JPMA
◉ PhRMA
Standing Regulatory Members
◉ Health Canada, Canada
◉ Swissmedic, Switzerland
Regulatory Members
◉ ANVISA, Brazil
◉ HSA, Singapore
◉ MFDS, Republic of Korea
◉ NMPA, China
◉ SFDA, Saudi Arabia
◉ TFDA, Chinese Taipei
◉ TITCK, Turkey
Industry Members
◉ BIO
◉ Global Self-Care Federation
◉ IGBA
10. ICH Guidelines for Pharmacovigilance
◉ The ICH has published a number of documents setting
standards for safety, both clinical and pre-clinical.
◉ Pre-clinical guidelines have an “S” designation e.g. S1, S2
etc. It should be noted that the clinical safety guidelines are
designated as “E”
◉ These documents provide a high degree of detail about the
expected manner, method, timing, frequency and
circumstances in which pharmaceutical companies and other
relevant parties need to report suspected adverse reactions
and other vital clinical data to the regulatory authorities.
11. ICH Guidelines for Pharmacovigilance
◉ Each of the following clinical safety guideline has an identifying code, and
during the lifetime of the ICH the codes have already been revised to reflect the
development and evolution of those standards documents:
E1 Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life
Threatening Conditions
E2A Clinical Safety Data Management: Definitions and Standards for
Expedited Reporting
E2B (R2) Maintenance of the Clinical Safety Data Management including
Data Elements for Transmission of Individual Case Safety Reports
E2B (R3) Clinical Safety Data Management: Data Elements for Transmission
of Individual Case Safety Reports
12. ICH Guidelines for Pharmacovigilance
E2C (R1) Clinical Safety Data Management: Periodic Safety Update Reports for
Marketed Drugs
E2C (R2) Periodic Benefit-Risk Evaluation Report
E2D Post-Approval Safety Data Management: Definitions and Standards for
Expedited Reporting
E2E Pharmacovigilance Planning
E2F Development Safety Update Report
14. EXPEDITED REPORTING
CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND
STANDARDS FOR EXPEDITED REPORTING (E2A)
It is important to harmonise the way to gather and, if necessary, to take
action on important clinical safety information arising during clinical
development. Thus, agreed definitions and terminology, as well as
procedures, will ensure uniform Good Clinical Practice standards in this
area.
This guideline addresses the following:
1. the development of standard definitions and terminology for key
aspects of clinical safety reporting, and
2. the appropriate mechanism for handling expedited (rapid) reporting, in
the investigational (i.e., pre-approval) phase.
15. EXPEDITED REPORTING
◉ Expedited Report: SAEs which are unexpected (not labelled), be
reported in 15 Calendar days from the first notification of anyone
in the company including its agent, business partners, contractors,
distributors, and vendors. Also known as alert report, 15-day
report.
◉ 7-day report: Patient in question has died or had life threatening
SAE which is also unexpected and possibly related. This report
should be sent to the health authorities within 7 calendar days.
Note: All 7-day reports are also 15-day report. It must also be followed
up as a 15 day report
16. EXPEDITED REPORTING
STANARDS FOR EXPEDITED REPORTING
What Should be Reported?
1. Single Cases of Serious, Unexpected ADRs:
◉ All adverse drug reactions (ADRs) that are both serious and unexpected are
subject to expedited reporting.
◉ This applies to reports from spontaneous sources and from any type of
clinical or epidemiological investigation, independent of design or purpose.
◉ Information obtained by a sponsor or manufacturer on serious, unexpected
reports from any source should be submitted on an expedited basis to
appropriate regulatory authorities if the minimum criteria for expedited
reporting can be met.
◉ Causality assessment is required for clinical investigation cases.
17. EXPEDITED REPORTING
2. Other Observations:
◉ There are situations in addition to single case reports of "serious"
adverse events or reactions that may necessitate rapid
communication to regulatory authorities
Examples include:
◉ For an "expected," serious ADR, an increase in the rate of
occurrence which is judged to be clinically important.
◉ A significant hazard to the patient population, such as lack of
efficacy with a medicinal product used in treating life-threatening
disease.
18. EXPEDITED REPORTING
STANARDS FOR EXPEDITED REPORTING
Whom Should be Reported?
Determination Sponsor Investigator
Serious/Life-Threatening Yes Yes
Causality (Responsible Possibility) Yes Yes
Expectedness (Labeled/Unlabeled) Yes Yes
19. EXPEDITED REPORTING
1. Fatal or Life-Threatening Unexpected ADRs
◉ Fatal or life-threatening, unexpected ADRs occurring in
clinical investigations qualify for very rapid reporting.
Regulatory agencies should be notified (e.g., by telephone,
facsimile transmission, or in writing) as soon as possible but
no later than 7 calendar days after first knowledge by the
sponsor that a case qualifies, followed by as complete a
report as possible within 8 additional calendar days.
Reporting Time Frames:
20. EXPEDITED REPORTING
2. All Other Serious, Unexpected ADRs
◉ Serious, unexpected reactions (ADRs) that are not fatal or life-
threatening must be filed as soon as possible but no later than 15
calendar days after first knowledge by the sponsor
3. Minimum criteria for reporting
◉ An identifiable patient; a suspect medicinal product; an identifiable
reporting source; and an event or outcome that can be identified as
serious and unexpected, and for which, in clinical investigation
cases, there is a reasonable suspected causal relationship.
Reporting Time Frames:
21. EXPEDITED REPORTING
How to Report:
◉ The CIOMS-I form has been a widely accepted standard for
expedited adverse event reporting. However, no matter what the
form or format used, it is important that certain basic
information/data elements, when available, be included with any
expedited report, whether in a tabular or narrative presentation.
◉ All reports must be sent to those regulators or other official parties
requiring them in countries where the drug is under development.
28. Individual Case Safety Reports (ICSR)
◉ It is a document providing the most complete
information related to an individual case at a certain
point of time.
◉ An Individual Case Study Report (ICSR) is a safety service
document which includes information required for reporting
the adverse events and problems related to products and
complaints filed by consumers with respect to any product.
◉ It is an important facet of adverse event reporting which is a
source of data in PV (pharmacovigilance).
29. Individual Case Safety Reports (ICSR)
Sources of individual case safety reports
1. Unsolicited Sources
■ Spontaneous reports
■ Literature
■ Internet
■ Other sources- such as lay press and other media
2. Solicited sources
3. Contractual Agreements
4. Regulatory Authority Sources
30. Individual Case Safety Reports (ICSR)
◉ Because of national and international agreements, rules, and
regulations, individual case safety reports of adverse drug reactions
and adverse events need to be transmitted
from identified reporting sources to regulatory authorities and
pharmaceutical companies;
between regulatory authorities;
between pharmaceutical companies and regulatory
authorities;
within authorities or pharmaceutical companies;
from clinical investigators, via the sponsor, to ethics
committees;
from authorities to the World Health Organization (WHO)
Collaborating Center for International Drug Monitoring.
31. Individual Case Safety Reports (ICSR)
◉ The transmission of such individual case safety reports
currently relies on paper-based formats (e.g., Yellow cards,
CIOMS forms, MedWatch) or electronic media.
◉ Considering the large number of potential participants in a
world-wide exchange of information, there is a need for an
electronic format capable of accommodating direct database
to database transmission
32. Individual Case Safety Reports (ICSR)
◉ Successful electronic transmission of information relies on
the definition of common data elements and standard
transmission procedures
◉ The format for individual case safety reports includes
provisions for transmitting all the relevant data elements
useful to assess an individual adverse drug reaction or
adverse event report. Structured data are strongly
recommended in electronic transmission.
33. Individual Case Safety Reports (ICSR)
Minimum information:
◉ The minimum information for the transmission of a report
should include at least one identifiable patient (section B.1),
one identifiable reporter (section A.2), one reaction/event
(section B.2), and one suspect drug (section B.4).
◉ Because it is often difficult to obtain all the information, any
one of several data elements is considered sufficient to
define an identifiable patient or an identifiable reporter.
34. Individual Case Safety Reports (ICSR)
◉ It is also recognized that the patient and the reporter can be
the same individual and still fulfill the minimum reporting
criteria.
◉ In addition, to properly process the report, the following
administrative information should be provided: the sender’s
(case) safety report unique identifier (A.1.0.1), the date of
receipt of the most recent information (A.1.7), the
worldwide unique case identification number (A.1.10) and
the sender identifier (A.3.1.2).
36. Elements of the specifications in the ICSR
◉ Pre-Clinical:
Toxicity
General Pharmacology
Drug Interactions
Other toxicity related information
◉ Clinical:
Limitations of the Human Safety Database
Populations not studied in the pre-approval phase
Adverse events/adverse drug reactions
Identified risks that require further evaluation
Potential risks that require further evaluation
Identified and potential interactions
38. PERIODIC SAFETY UPDATE REPORTS
◉ The periodic safety update report (PSUR) is a document that
allows a periodic, comprehensive assessment of the worldwide
safety data of a marketed drug or biological product.
◉ The concept evolved from the Council for International
Organizations of Medical Sciences (CIOMS) Working Group II
report (CIOMS, 1992).
◉ The PSUR creates the opportunity for a periodic overall safety
evaluation to show whether a product’s safety profile has remained
the same or has undergone change since it was authorized and to
indicate whether changes should be made to product information
to optimize the use of a product.
39. PERIODIC SAFETY UPDATE REPORTS
Purpose of the PSUR:
◉ The reason such a review is needed periodically is because clinical
trials tend to be of short duration and to include a limited number of
patients.
◉ Moreover, clinical trials have inclusion and exclusion criteria. After a
product is launched, it may be used by patients not studied in clinical
trials, for example children, the elderly, pregnant or breastfeeding
women or patients with comorbidities such as hepatic or renal disease.
◉ After approval, a drug becomes so available for immediate use in large
populations, so rare adverse drug reactions (ADRs) can be more easily
identified. The drugs also become available for indefinite use (unless
prescribing information indicates otherwise), and delayed onset ADRs
become easier to identify.
40. PSUR – GENERAL PRINCIPLES
ONE REPORT FOR PRODUCTS CONTAINING ONE ACTIVE SUBSTANCE
AUTHORISED TO ONE MARKETING AUTHORISATION HOLDER
◉ Ordinarily, all dosage forms and formulations as well as
indications for a given pharmacologically active substance
authorized to one marketing authorization holder (MAH) may be
covered in one PSUR.
◉ Within the single PSUR, separate presentations of data for
different dosage forms, indications or populations (e.g. children
versus adults) may be appropriate.
41. PSUR – GENERAL PRINCIPLES
PRODUCTS AUTHORISED TO MORE THAN ONE MAH
◉ Each MAH is responsible for submitting PSURs, even if different
companies market the same product in the same country.
COMBINATION PRODUCTS
◉ Safety information for the fixed combination may be reported
either in a separate PSUR or included as separate presentations in
the report for one of the separate components, depending on the
circumstances.
42. PERIODIC SAFETY UPDATE REPORTS
GENERAL SCOPE OF INFORMATION
◉ All relevant clinical and non-clinical safety data should cover only
the period of the report (interval data).
Exception- Regulatory status information on authorization
application and data on serious unlisted ADRs- can be provided
with cumulative summary tabulations.
◉ The safety information contained within the PSUR comes from a
variety of different sources. These include spontaneous reports of
adverse events from different countries, the literature, clinical
trials, registries, regulatory ADR databases and important animal
findings.
43. PERIODIC SAFETY UPDATE REPORTS
◉ Reports of lack of efficacy specifically for drugs used in the
treatment of life-threatening conditions and for certain other
medicinal products, such as contraceptives and vaccines, may
represent a significant hazard, and in that sense may be a safety
issue. These types of cases should be discussed in the PSUR.
Frequency of reporting
◉ Each PSUR should cover the period since the last update report.
The need for a report and the frequency of report submission to
authorities are subject to local regulatory requirements. The age of
a medicinal product on the market may influence this process.
44. PERIODIC SAFETY UPDATE REPORTS
◉ In the EU, reports be submitted every 6 months for the first 2 years
after authorization, annually for the three following years and then
five yearly
◉ In the United States, the FDA requires quarterly reports during the
first 3 years, then annual reports; and
◉ In Japan, the authorities require annual survey report on a cohort of
a few thousand patients established by a certain number of
identified institutions during the 6 years following authorization.
◉ Regarding other marketing experience, adverse reactions which are
non-serious, but both mild in severity and unlabeled, must be
reported every 6 months for 3 years and annually thereafter.
46. PSUR Content
TITLE
◉ PSURs contain proprietary information, so the title page should contain a statement
on the confidentiality of the data and conclusions included in the report.
EXECUTIVE SUMMARY
◉ The executive summary should consist of a brief overview providing the reader with a
description of the most important information.
INTRODUCTION
◉ The introduction puts the report in context, describing those products/formulations
that are included and excluded, outlining the pharmacology of the product, its
indications (both marketed and in clinical trials)
WORLDWIDE MARKETING AUTHORISATION STATUS
◉ The PSUR should include a short summary of the worldwide marketing authorisation
status
47. PSUR Content
UPDATE ON REGULATORY AUTHORITY OR MAH ACTIONS TAKEN FOR
SAFETY REASONS
◉ The update on regulatory authority or MAH actions taken for safety reasons
refers to marketing authorization, withdrawal or suspension; failure to obtain a
marketing authorization renewal; restrictions on distribution; clinical trial
suspension; dosage modification/formulation changes and changes in target
population or indications.
CHANGES IN REFERENCE SAFETY INFORMATION
◉ The changes in reference safety information section refers to changes in the
CCSI (company core safety information). The CCDS (company core data sheet),
which incorporates the CCSI, should be included as an appendix.
48. PSUR Content
PATIENT EXPOSURE
◉ Patient exposure refers to both market exposure and clinical trials (if relevant).
Estimates of patient exposure for marketed drugs often rely on gross
approximations of in-house or purchased sales data or volume.
PRESENTATION OF INDIVIDUAL CASE HISTORIES
◉ There is no specific guidance in E2C on the presentation of individual case
histories, but because it is impractical to present all case reports for the reporting
period, a brief description of the criteria used to select cases for presentation
should be given.
◉ This section of the PSUR should contain a description and analysis of selected
cases, including fatalities, presenting new and relevant safety information and
grouped by medically relevant headings
49. PSUR Content
STUDIES
◉ Studies refer to only those company-sponsored studies and published safety
studies, including epidemiology studies, that produce findings with potential
impact on product safety information.
OTHER INFORMATION
◉ Other information may include risk management programmes the MAH has put
in place and/or a benefit–risk analysis report.
◉ If such an analysis has been conducted separately, a summary of the analysis
should be included in this section.
◉ This section can also include important information received after the DLP (data
lock point).
50. PSUR Content
OVERALL SAFETY EVALUATION
◉ The overall safety evaluation should highlight new information on serious and
non-serious unlisted ADRs. If there are no new safety issues, this should be
stated with a note that the information is in keeping with the established safety
profile. This section should also review reports of
○ drug interactions;
○ overdose: deliberate or accidental and treatment;
○ abuse or misuse;
○ pregnancy or lactation: positive and negative experiences;
○ special patient groups (e.g. children, elderly, organ
○ impaired) and
○ effects of long-term treatment.
51. PSUR Content
CONCLUSION
◉ The conclusion should indicate safety data which are not in accordance with
previous experience and/or with the CCSI and specify and justify any action
recommended or initiated.
52. PSUR process
A. Intake of ADR information
B. Case processing
C. Data retrieval
D. Data analysis and
E. Medical review and risk assessment
52
54. Post approval safety management guideline
Post approval safety management (E2D) guideline was
finalized in 2003 and provides a standardized procedure for
post approval safety data management, including post
approval expedited reporting to the concerned authority.
It parallels and adds to the E2A document, which covered
preapproval (clinical trial) safety data management, by
covering postmarketing safety data management.
This document standardizes data management of cases from
consumers, literature, internet, and other types of
postmarketing cases.
55. DEFINITIONS
i. Adverse Event
ii. ADR
iii. Serious AE/ADR
iv. Unexpected ADR
v. Healthcare professional: Any medically-qualified person
such as a physician, dentist, pharmacist, nurse, coroner, or as
otherwise specified by local regulations.
vi. Consumer: A person who is not a healthcare professional,
such as patient, lawyer, friend or relative of the patient.
56. SOURCES
1. Unsolicited Sources
Spontaneous reports
Literature
Internet
Other sources- such as lay press and other media
2. Solicited sources
3. Contractual Agreements
4. Regulatory Authority Sources
57. STANDARDS FOR EXPEDITED REPORTING
◉ Serious ADRs:
Serious and unexpected cases of ADRs are subject to
expedited reporting.
For reports from studies and other solicited sources, all
cases judged by either the reporting health care
professionals or the MAH for causal relationship to the
medicinal product qualifying as ADRs.
Spontaneous reports associated with approved drugs
imply a possible causality
58. STANDARDS FOR EXPEDITED REPORTING
◉ Other observations:
Any significant unanticipated safety findings, including in
vitro, animal, epidemiologic, or clinical studies, that
suggest a significant human risk and could change the
benefit–risk evaluation should be communicated to the
regulatory authorities as soon as possible.
Lack of efficacy observations should not be expedited but
should be discussed in PSURs unless local requirements
oblige their being expedited.
59. STANDARDS FOR EXPEDITED REPORTING
Overdoses with no associated adverse outcome should not be
reported as adverse reactions.
Minimum criteria for reporting include an identifiable reporter, an
identifiable patient, an adverse reaction, and a suspect product.
Reporting time frames for expedited reports are normally 15
calendar days from initial receipt of the minimal information by
any personnel of the MAH. This is day 0. Additional medically
relevant information for a previously submitted report restarts the
clock.
Non-serious ADRs are not normally expeditable whether expected
or not
61. PHARMACOVIGILANCE PLANNING
This guideline was finalized in 2004 and is
intended to aid in planning pharmacovigilance
activities, especially in preparation for the early
postmarketing period of a new drug.
The main focus of this guideline is on a Safety
Specification and Pharmacovigilance Plan that
might be submitted at the time of the application
for marketing.
62. PHARMACOVIGILANCE PLANNING
All three regions of the ICH (United States,
European Union, and Japan) have been turning
their attention to risk management and
pharmacovigilance planning throughout the life
cycle of a drug.
This document reflects ICH’s views.
63. Principles of Pharmacovigilance Planning
guidelines
i. Planning of pharmacovigilance activities
throughout the product life cycle
ii. Science-based approach to risk documentation
iii. Effective collaboration between regulators and
industry
iv. Applicability of the pharmacovigilance plan across
the three ICH region
64. Sections of Pharmacovigilance Plan
1. Safety Specification
2. Pharmacovigilance plan
3. Annex-Pharmacovigilance methods
65. Sections of Pharmacovigilance Plan
1. Safety Specification:
The safety specification is a summary of the
important identified risks of a drug, important
potential risks, and important missing information.
It should refer to the three safety sections in the
Common Technical Document:
Non-clinical
Clinical
Epidemiology
66. Sections of Pharmacovigilance Plan
2. Pharmacovigilance Plan:
The pharmacovigilance plan should be based on the safety
specification and developed by the sponsor.
This includes:
• Summary of ongoing safety issues, including the important
identified risks, potential risks, and missing information.
• Routine pharmacovigilance practice
• Summary of actions to be completed, including milestones
67. Sections of Pharmacovigilance Plan
3. Pharmacovigilance Methods:
The best method to address a specific situation may vary
depending on the product, indication, population treated.
Sponsors should choose the most appropriate design.
Design and conduct of observational studies
Annexure - A detailed discussion of pharmacovigilance
methods is appended to the document.
69. GOOD CLINICAL PRACTICES (GCP)
◉ GCPs are stand alone document and its guidelines are given
in ICH E6.
◉ Good Clinical Practice (GCP) is an international ethical and
scientific quality standard for designing, conducting,
recording and reporting trials that involve the participation
of human subjects.
◉ Compliance with this standard provides public assurance
that the rights, safety, and well-being of trial subjects are
protected, consistent with the principles that have their
origin in the Declaration of Helsinki, and that the clinical
trial data are credible.
69
70. GOOD CLINICAL PRACTICES (GCP)
1) Clinical trials should be conducted in accordance with the ethical principles
that have their origin in the Declaration of Helsinki, and that are consistent
with GCP and the applicable regulatory requirement(s).
2) Before a trial is initiated, foreseeable risks and inconveniences should be
weighed against the anticipated benefit for the individual trial subject and
society. A trial should be initiated and continued only if the anticipated
benefits justify the risks.
3) The rights, safety, and well-being of the trial subjects are the most
important considerations and should prevail over interests of science and
society.
4) The available nonclinical and clinical information on an investigational
product should be adequate to support the proposed clinical trial.
70
71. GOOD CLINICAL PRACTICES (GCP)
5) Clinical trials should be scientifically sound, and described in a clear,
detailed protocol.
6) A trial should be conducted in compliance with the protocol that has
received prior institutional review board (IRB)/independent ethics
committee (IEC) approval/favourable opinion.
7) The medical care given to, and medical decisions made on behalf of,
subjects should always be the responsibility of a qualified physician or,
when appropriate, of a qualified dentist.
8) Each individual involved in conducting a trial should be qualified by
education, training, and experience to perform his or her respective
task(s).
9) Freely given informed consent should be obtained from every subject
prior to clinical trial participation.
71
72. GOOD CLINICAL PRACTICES (GCP)
10)All clinical trial information should be recorded, handled, and
stored in a way that allows its accurate reporting, interpretation and
verification.
11) The confidentiality of records that could identify subjects should
be protected, respecting the privacy and confidentiality rules in
accordance with the applicable regulatory requirement(s).
12) Investigational products should be manufactured, handled, and
stored in accordance with applicable good manufacturing practice
(GMP). They should be used in accordance with the approved
protocol.
13)Systems with procedures that assure the quality of every aspect of
the trial should be implemented.
72
73. GOOD CLINICAL PRACTICES (GCP)
INVESTIGATOR’S RESPONSIBILITIES:
All SAEs should be reported immediately by the investigator to the
sponsor except for those SAEs which the protocol or other document
identifies not needing immediate reporting.
Identify the subject by trial code number rather than by subject name,
personal information and/or address
Investigator should comply with the applicable regulatory requirement
while reporting unexpected SAEs to the regulatory authorities
Adverse events or laboratory abnormalities should be reported to the
Sponsor within the time periods specified by sponsor.
For reported death, the investigator should provide additional information
if requested by sponsor or IRB/IEC.
73
74. GOOD CLINICAL PRACTICES (GCP)
INVESTIGATOR’S RESPONSIBILITIES:
If the investigator terminates or suspended trial without prior agreement of
the sponsor, the investigator should promptly inform the institute and
where applicable (such as Institutions, IRB/IEC) by providing detailed
information.
If the sponsor terminates or suspended trial, the investigator should
promptly inform the institutes and where applicable (such as Institutions,
IRB/IEC) by providing detailed information.
If IRB/IEC terminates or suspends its approval/favourable opinion of a
trial, the investigator should inform the institution where applicable.
74
75. GOOD CLINICAL PRACTICES (GCP)
SPONSOR’S RESPONSIBILITIES:
Sponsor is responsible for the ongoing safety
evaluation of the investigational product(s).
Should notify all concerned
investigator(s)/institution(s) and the regulatory
authorities of findings that could adverse affect
the safety of subjects, impact the conduct of trial.
75
76. GOOD CLINICAL PRACTICES (GCP)
ADR Reporting guidelines:
Sponsor should expedite the reporting to all concerned
investigator(s)/Institution(s) to the IRB/IEC, where required
to the regulatory authority of all ADRs that are both serious
and unexpected.
Expedited reports should comply with the applicable
regulatory requirement and with the ICH guidelines for
clinical safety data management.
Sponsor should submit to the regulatory authority(ies) all
safety updates and periodic reports as required by applicable
regulatory requirement(s).
76
77. REFERENCES
1. Borton Cobert. Cobert’s Manual of Drug Safety and
Pharmacovigilance. 2nd Edition. Jones and Bartlett
Learning. 2012.
2. Dr. S. B. Bhise, Mrs. M.S. Bhise. Pharmacovigilance.
Nirali Prakashan. 1st Edition. February 2021.
3. Dr. D. K. Tripathi, Dr. Shiv Shankar Shukla, Dr. Ravindra
Kumar Pandey. Pharmacovigilance. Nirali Prakashan. 2nd
Edition. February 2021.
4. Elizabeth B. Andrews, Nicholas Moore. Mann’s
Pharmacovigilance. 3rd Edition. Wiley Blackwell. 2014.
77